HR Execs on the Move

Syneos Health

www.syneoshealth.com

 
"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Chris Hodes
Regional Sales Director Profile
Steve O'Brien
SVP, Talent Acquisition Profile
Hillary Bochniak
Chief Human Resources Officer Profile
Robyn Aycock
Regional Sales Director-Southeast Profile
Stanford Rudnick
Interim Chief Financial Officer and Chief Strategy Officer Profile

Similar Companies

Sovereign Pharmaceuticals

Sovereign Pharmaceuticals is your ideal CDMO partner for your pharma product development, formulation, fill/finish, packaging & commercial manufacturing needs.

Lehigh Valley Technology

Lehigh Valley Technology is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Antigen Laboratories Inc

Antigen Laboratories Inc is a Liberty, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MOVA Pharmaceuticals

MOVA Pharmaceuticals is a Caguas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.